Tag: options

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men¹—and encourages them to take control of their health.

Talen enters power purchase agreement for 1,920 megawatts of carbon-free electricity at full quantity to support Amazon operations, and explore SMR technology

FORM 8.3

Downing LLP
LEI: 213800G3X76VBG9SB504
11 June 2025
Form 8.3 re. Marlowe Plc

FORM 8.5 (EPT/RI)

London, UK, 11 June 2025 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been granted a patent by the European Patent Office for PP353, its clinical stage asset.

MONTREAL, June 10, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that its bottling subsidiary, formerly known as Triani Canada Inc. (“Triani”), has been placed into receivership and has ceased operations. Triani’s receivership was ordered on June 10, 2025, by the Superior Court, District of Montreal, at the request of Triani's principal creditors pursuant to Section 243 of the Bankruptcy and Insolvency Act (Canada), as disclosed in the Company's press release dated April 7, 2025.

MONTRÉAL, 10 juin 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce la mise sous séquestre de sa filiale d’embouteillage, anciennement connue sous le nom de Triani Canada Inc. (« Triani »), et la cessation des activités de sa filiale. La mise sous séquestre de Triani a été ordonnée le 10 juin 2025 par la Cour supérieure, district de Montréal, à la demande des principaux créanciers de Triani en vertu de l'article 243 de la Loi sur la faillite et l'insolvabilité (Canada), tel que divulgué dans le communiqué de presse de la Société du 7 avril 2025.

Updated Virtual Weight Loss Platform Expands Access to GLP-1 Support and Clinician-Guided Obesity Care Across All 50 States

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.